Ucla Hematology/Oncology
Los Angeles, California 90095
We've found
8 trials
at this facility
Advanced Solid Tumors Clinical Trial
Updated: 12/31/1969
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumor Clinical Trial
Updated: 12/31/1969
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Cancer Clinical Trial
Updated: 12/31/1969
Open-Label Extension and Safety Study of Talazoparib
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Renal Cell Carcinoma Clinical Trial
Updated: 12/31/1969
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
PF-06804103 Dose Escalation in HER2 Positive Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer Clinical Trial
Updated: 12/31/1969
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neoplasm Clinical Trial
Updated: 12/31/1969
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials